OBJECTIVES: Testicular cancer has one of the highest 5-year survival rates of all cancer sites. The survival period is marked by an increased risk of secondary cancer and cardiovascular events owing to treatment-related toxicities. The purposes of this cross-sectional study were to determine the prevalence of health behaviors and depressive symptoms and to assess the relationship between depression and health behaviors in survivors of testicular cancer. METHODS: A total of 162 survivors of testicular cancer 2 to 10 years after their diagnosis completed a one-time telephone interview. The interview included a battery of questions from the Behavioral Risk Factor Surveillance System assessing health behaviors (smoking, physical activity, cholesterol screening, colorectal cancer screening, alcohol consumption, and fruit and vegetable intake) and the Centers for Epidemiological Studies-Depression (CES-D) questionnaire assessing depressive symptoms. RESULTS: The interviews revealed a low prevalence of positive health behaviors among survivors of testicular cancer. The percentage (17.5%) of survivors of testicular cancer who scored above the cutoff on the CES-D was greater than that (11%) of large-scale population-based estimates in men aged 19 to 44 years. Smoking was significantly related to depression. Depressive symptoms (CES-D score) differed significantly depending on smoking status (current smokers, mean = 15.2; former smokers, mean = 6.2, P <0.001; and never smokers, mean = 8.7, P <0.001). CONCLUSIONS: Given the increased risk of cancer and treatment-related morbidities of these survivors, the findings of this study suggest that healthcare professionals should encourage survivors of testicular cancer to engage in positive health behaviors and check for depressive symptoms.
OBJECTIVES:Testicular cancer has one of the highest 5-year survival rates of all cancer sites. The survival period is marked by an increased risk of secondary cancer and cardiovascular events owing to treatment-related toxicities. The purposes of this cross-sectional study were to determine the prevalence of health behaviors and depressive symptoms and to assess the relationship between depression and health behaviors in survivors of testicular cancer. METHODS: A total of 162 survivors of testicular cancer 2 to 10 years after their diagnosis completed a one-time telephone interview. The interview included a battery of questions from the Behavioral Risk Factor Surveillance System assessing health behaviors (smoking, physical activity, cholesterol screening, colorectal cancer screening, alcohol consumption, and fruit and vegetable intake) and the Centers for Epidemiological Studies-Depression (CES-D) questionnaire assessing depressive symptoms. RESULTS: The interviews revealed a low prevalence of positive health behaviors among survivors of testicular cancer. The percentage (17.5%) of survivors of testicular cancer who scored above the cutoff on the CES-D was greater than that (11%) of large-scale population-based estimates in men aged 19 to 44 years. Smoking was significantly related to depression. Depressive symptoms (CES-D score) differed significantly depending on smoking status (current smokers, mean = 15.2; former smokers, mean = 6.2, P <0.001; and never smokers, mean = 8.7, P <0.001). CONCLUSIONS: Given the increased risk of cancer and treatment-related morbidities of these survivors, the findings of this study suggest that healthcare professionals should encourage survivors of testicular cancer to engage in positive health behaviors and check for depressive symptoms.
Authors: Alexandra W van den Belt-Dusebout; Janine Nuver; Ronald de Wit; Jourik A Gietema; Wim W ten Bokkel Huinink; Patrick T R Rodrigus; Erik C Schimmel; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: M T Meinardi; J A Gietema; W T van der Graaf; D J van Veldhuisen; M A Runne; W J Sluiter; E G de Vries; P B Willemse; N H Mulder; M P van den Berg; H S Koops; D T Sleijfer Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Melissa Y Carpentier; J Dennis Fortenberry; Mary A Ott; Mary J Brames; Lawrence H Einhorn Journal: Psychooncology Date: 2010-05-20 Impact factor: 3.894
Authors: Chunkit Fung; Howard D Sesso; Annalynn M Williams; Sarah L Kerns; Patrick Monahan; Mohammad Abu Zaid; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Christian K Kollmannsberger; Ryan Cook; Sandra Althouse; Shirin Ardeshir-Rouhani-Fard; Steve E Lipshultz; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis Journal: J Clin Oncol Date: 2017-02-27 Impact factor: 44.544
Authors: Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa Journal: J Natl Cancer Inst Date: 2010-06-28 Impact factor: 13.506
Authors: Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis Journal: J Clin Oncol Date: 2018-04-04 Impact factor: 44.544
Authors: Shirin ArdeshirRouhaniFard; Paul C Dinh; Patrick O Monahan; Sophie D Fossa; Robert Huddart; Chunkit Fung; Yiqing Song; Darren R Feldman; Robert J Hamilton; David J Vaughn; Neil E Martin; Christian Kollmannsberger; Lawrence Einhorn; Kurt Kroenke; Lois B Travis Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-04-13 Impact factor: 4.254
Authors: J Beyer; P Albers; R Altena; J Aparicio; C Bokemeyer; J Busch; R Cathomas; E Cavallin-Stahl; N W Clarke; J Claßen; G Cohn-Cedermark; A A Dahl; G Daugaard; U De Giorgi; M De Santis; M De Wit; R De Wit; K P Dieckmann; M Fenner; K Fizazi; A Flechon; S D Fossa; J R Germá Lluch; J A Gietema; S Gillessen; A Giwercman; J T Hartmann; A Heidenreich; M Hentrich; F Honecker; A Horwich; R A Huddart; S Kliesch; C Kollmannsberger; S Krege; M P Laguna; L H J Looijenga; A Lorch; J P Lotz; F Mayer; A Necchi; N Nicolai; J Nuver; K Oechsle; J Oldenburg; J W Oosterhuis; T Powles; E Rajpert-De Meyts; O Rick; G Rosti; R Salvioni; M Schrader; S Schweyer; F Sedlmayer; A Sohaib; R Souchon; T Tandstad; C Winter; C Wittekind Journal: Ann Oncol Date: 2012-11-14 Impact factor: 32.976